» Articles » PMID: 24438162

Structure of Cyclin G-associated Kinase (GAK) Trapped in Different Conformations Using Nanobodies

Abstract

GAK (cyclin G-associated kinase) is a key regulator of clathrin-coated vesicle trafficking and plays a central role during development. Additionally, due to the unusually high plasticity of its catalytic domain, it is a frequent 'off-target' of clinical kinase inhibitors associated with respiratory side effects of these drugs. In the present paper, we determined the crystal structure of the GAK catalytic domain alone and in complex with specific single-chain antibodies (nanobodies). GAK is constitutively active and weakly associates in solution. The GAK apo structure revealed a dimeric inactive state of the catalytic domain mediated by an unusual activation segment interaction. Co-crystallization with the nanobody NbGAK_4 trapped GAK in a dimeric arrangement similar to the one observed in the apo structure, whereas NbGAK_1 captured the activation segment of monomeric GAK in a well-ordered conformation, representing features of the active kinase. The presented structural and biochemical data provide insight into the domain plasticity of GAK and demonstrate the utility of nanobodies to gain insight into conformational changes of dynamic molecules. In addition, we present structural data on the binding mode of ATP mimetic inhibitors and enzyme kinetic data, which will support rational inhibitor design of inhibitors to reduce the off-target effect on GAK.

Citing Articles

Site-Specific Competitive Kinase Inhibitor Target Profiling Using Phosphonate Affinity Tags.

van Bergen W, Nederstigt A, Heck A, Baggelaar M Mol Cell Proteomics. 2025; 24(2):100906.

PMID: 39826875 PMC: 11889359. DOI: 10.1016/j.mcpro.2025.100906.


From discovery to treatment: tracing the path of hepatitis E virus.

Letafati A, Taghiabadi Z, Roushanzamir M, Memarpour B, Seyedi S, Farahani A Virol J. 2024; 21(1):194.

PMID: 39180020 PMC: 11342613. DOI: 10.1186/s12985-024-02470-3.


A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2.

Dederer V, Murillo M, Karasmanis E, Hatch K, Chatterjee D, Preuss F J Biol Chem. 2024; 300(7):107469.

PMID: 38876305 PMC: 11284679. DOI: 10.1016/j.jbc.2024.107469.


Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons.

Rizk S, Moustafa D, ElBanna S, Nour El-Din H, Attia A World J Microbiol Biotechnol. 2024; 40(7):209.

PMID: 38771414 PMC: 11108896. DOI: 10.1007/s11274-024-03990-4.


Synthesis of a 3,7-Disubstituted Isothiazolo[4,3-]pyridine as a Potential Inhibitor of Cyclin G-Associated Kinase.

Grisez T, Ravi N, Froeyen M, Schols D, Meervelt L, De Jonghe S Molecules. 2024; 29(5).

PMID: 38474466 PMC: 10934046. DOI: 10.3390/molecules29050954.


References
1.
Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

2.
Zhang K, Cowtan K, Main P . Combining constraints for electron-density modification. Methods Enzymol. 1997; 277:53-64. DOI: 10.1016/s0076-6879(97)77006-x. View

3.
Dy G, Adjei A . Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013; 63(4):249-79. DOI: 10.3322/caac.21184. View

4.
Nguyen-Duc T, Peeters E, Muyldermans S, Charlier D, Hassanzadeh-Ghassabeh G . Nanobody(R)-based chromatin immunoprecipitation/micro-array analysis for genome-wide identification of transcription factor DNA binding sites. Nucleic Acids Res. 2013; 41(5):e59. PMC: 3597646. DOI: 10.1093/nar/gks1342. View

5.
Dumoulin M, Last A, Desmyter A, Decanniere K, Canet D, Larsson G . A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature. 2003; 424(6950):783-8. DOI: 10.1038/nature01870. View